Metformin Inhibits Gluconeogenesis by a Redox-Dependent Mechanism In Vivo

Metformin, the universal first-line treatment for type 2 diabetes, exerts its therapeutic glucose-lowering effects by inhibiting hepatic gluconeogenesis. However, the primary molecular mechanism of this biguanide remains unresolved, though it has been suggested to act, at least partially, by mitocho...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Med
Autors principals: Madiraju, Anila K., Qiu, Yang, Perry, Rachel J., Rahimi, Yasmeen, Zhang, Xian-Man, Zhang, Dongyan, Camporez, João-Paulo G., Cline, Gary W., Butrico, Gina M., Kemp, Bruce E., Casals, Gregori, Steinberg, Gregory R., Vatner, Daniel F., Petersen, Kitt Falk, Shulman, Gerald I.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6129196/
https://ncbi.nlm.nih.gov/pubmed/30038219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0125-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars